Studies on intrahepatic cholangiocarcinoma observed poor prognosis and significantly high tumor mutational burden among the patients having a co-mutation of KRAS and TP53 compared to the wild type and single-mutation-harboring patients [108]. This evidence concerns the gene TP53 and neoplasm.